Treats chronic obstructive pulmonary disease (COPD). Sold as Yupelri. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Revefenacin (sold as Yupelri), first approved Nov 9, 2018, with 0 new uses approved and 0 published complete response letters.
| Yupelri | Part B | $184M | +5% | 29,928 |
| Yupelri | Part D | $9.6M | +33% | 2,028 |
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)COPD Exacerbation · University of Tennessee Graduate School of Medicine | Phase 4 | Not yet recruiting | Jul 23, 2026 |
| Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsCOPD (Chronic Obstructive Pulmonary Disease) · University of Tennessee Graduate School of Medicine | Phase 4 | Recruiting | Aug 21, 2025 |
| Nov 9, 2018 | YupelriNDA 210598 · New molecular entity | Mylan Ireland Ltd | 3 | Marketed |
| — | RevefenacinANDA 218088 | Lupin Inc. | 0 | Discontinued |
| — | RevefenacinANDA 218089 | Mankind Pharma Ltd | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA